Helsinn Group

Day 1 at #BIOEuropeSpring is underway in Lisbon! Back to back meetings, great energy, and plenty of new ideas already on the table. Luis Vieira, from our Business Development team, is onsite and carving out time for insightful discussions. If you’re attending, let’s make sure we connect. Looking forward to inspiring conversations! #Helsinn #Partnering

🗣️ "The way in which we collaborate, even if we are in different companies, can be inspiring also in our companies." – Alice Bossi, Recordati Rare Diseases. Here is the fourth episode of #VoicesOfPartnership, our video series featuring insights from some of our trusted commercial partners. This time, Alice Bossi and Stephane Eifler from @RecordatiD reflect on the key ingredients that make collaboration with Helsinn a success. #Partnership #Helsinn #Recordati

Happy Women’s Day from Helsinn! Today, we celebrate the women of Helsinn through a video featuring some of the many female colleagues who make a difference across our organization. Thank you for the passion, commitment, and energy you bring to Helsinn. Here’s to the strength, resilience, and brilliance of women everywhere - today and every day. #WomensDay #Helsinn #Empowerment

What does leadership really mean at Helsinn? With #InsideHelsinnCulture, we open the conversation and give the floor to our Executive Leadership Team to share the themes that shape our culture - all united by one guiding principle: patient centricity. We begin with Roberta Cannella, Chief Operating Officer, on "Operational Excellence & Innovation in Execution": from orchestrating diverse expertise across Operations to strengthening our global supply chain through tangible improvements in quality, efficiency, and sustainability. 👉 Swipe to read her perspective. #Helsinn50 #Leadership

March is #ColorectalCancerAwarenessMonth! For many people undergoing treatment for colorectal cancer, Chemotherapy-Induced Nausea and Vomiting (CINV) remains a significant challenge, with a real impact on quality of life and treatment adherence. We are committed to raising awareness about CINV and to supporting guideline-based prevention, helping ensure that risk factors are promptly identified and addressed. 👇Watch this video to learn more! #Helsinn #SupportiveCare Please note: some of the information contained in this post may be intended for healthcare professionals only.

Meet our Business Development Lead, Luis Vieira, at #BIOEuropeSpring, in Lisbon from 23-25 March 2026. Our current business development strategy is focused on in-licensing or commercial partnerships of late-stage assets (from Phase 2b onwards) in Supportive Care (related to Cancer or other therapy areas), niche Oncology, specialized Dermatology, Haematology and Transplants for our U.S. affiliate and/or worldwide rights. Luis looks forward to meeting you there! #Helsinn #Partnering #BusinessDevelopment

At Helsinn, we listen to the stories behind rare diseases: stories of complex journeys, uncertainty, and everyday resilience. On #RareDiseaseDay, we stand alongside patients, families, and caregivers, committed to transforming that resilience into better care. We continue to shine a light on Mycosis Fungoides-type Cutaneous T-cell Lymphoma (MF-CTCL), a rare skin lymphoma that is often challenging to diagnose. Greater awareness, early diagnosis, and continued research are essential to improving outcomes and bringing hope to those living with this disease. Swipe through our carousel and help raise awareness for rare disease communities. Join us in making a difference: take part in Rare Disease Day and learn more at rarediseaseday.org. #Helsinn #CutaneousLymphoma

Pleased to announce a strategic collaboration with InVirtuoLabs, combining our proprietary compound library with their generative AI platform to accelerate the discovery and development of novel small‑molecule therapeutics. Our Chief Business Officer and Deputy CEO, Gabriele Braglia, highlighted the value of this collaboration and its role in advancing innovation through next‑generation technologies. Read the full press release here: lnkd.in/ejWNgKJi #Helsinn #AI #Innovation

We are pleased to announce the European Commission approval of the new oral suspension formulation of netupitant/palonosetron! This milestone reinforces our commitment to advancing supportive cancer care by expanding the range of formulation options available to patients. Read the full press release here: lnkd.in/etv_v3Xq

We are pleased to announce our participation at #BIOEuropeSpring in Lisbon, on March 23–25, 2026. As we join the life sciences community, we look forward to exploring new partnering opportunities and connecting with innovators shaping the future of healthcare. Through our comprehensive platform, we offer a value‑added approach to bring partnered assets across regulatory, manufacturing, and commercial phases worldwide. Discover more about our business development strategy here: helsinn.com/business/busin… If you’re attending, we hope to meet you there! #Helsinn #Partnering

Delighted to announce that we have entered into a Licence, Distribution and Supply Agreement with @MagnaPharmGroup to support patients with chemotherapy-induced nausea and vomiting (CINV) across five Central and Eastern European countries. Riccardo Braglia, our Chairman and CEO, highlighted the importance of this new partnership and how it reinforces our mission to support cancer patients throughout their journey. Read the full press release here: helsinn.com/wp-content/upl… #Helsinn #SupportiveCare #Partnership

Excited to announce the expansion of our long-standing partnership with Esteve, to continue supporting patients with chemotherapy-induced nausea and vomiting (CINV), now also in Austria. Our Chairman and CEO, Riccardo Braglia, commented on the importance of this milestone and our ongoing commitment to patients. Read the full press release here: lnkd.in/ewTY8DT2 #Helsinn #SupportiveCare #Partnership

Today is #WorldCancerDay- a global initiative led by the @uicc. The theme, #UnitedByUnique, shines a light on the individual stories behind cancer - stories of pain, struggle, healing, resilience, love, and more. Each journey is unique, yet patients, together, create a powerful collective voice. In this spirit, we share the testimony of Diane, a patient who reflects on how she faced her diagnosis and what helped her keep moving forward during an incredibly difficult time. 🎥 Watch the video to hear Diane’s reflection. 🌐 Learn more or share your story at worldcancerday.org

On Data Privacy Day 2026, we reaffirm our dedication to building privacy, security, and ethics into every product and process. As digitalisation and AI reshape our world, we stay ahead by owning risks, documenting choices, and demonstrating compliance. Discover how we’re shaping the future of data protection. #DataPrivacyDay #Helsinn #Privacy #Compliance #AI

Day 2 at #JPM26! Excited to keep building connections with industry leaders and exploring collaborations that can truly advance patient care worldwide. Let’s connect and make it happen! #Helsinn #Pharma

As we enter our 50th anniversary year, we are excited to announce our new Executive Leadership Team, with Riccardo Braglia returning as CEO to lead Helsinn into the future. Watch this exclusive video interview, where our CEO shares Helsinn’s strategic priorities for its next chapter of growth. Read the full PR here: helsinn.com/news/helsinn-a… #Helsinn50 #NewLeadership #Strategy

Landed in San Francisco! Our team is ready for an intense four days of meetings, networking, and building connections at the J.P. Morgan Healthcare Conference 2026. Looking forward to engaging with partners and exploring new opportunities! #JPM26 #Helsinn #Pharma

We're pleased to share this new short video: Prevention is Key: Managing Nausea and Vomiting in ADC Therapy. This video reviews ADC-related nausea characteristics, guidelines & treatment strategies, complementary approaches, and patient education. #SuppOnc @OncoAlert